Alnylam reviews pre-clinical data from ALN-AS1 system for treatment of AIP Alnylam Pharmaceuticals, Inc . , a leading RNAi therapeutics organization, announced today that it provides presented essential pre-clinical proof-of-idea data from its RNAi therapeutic plan targeting aminolevulinate synthase-1 for the treating porphyria including severe intermittent porphyria . The new research findings were offered at the International Congress of Porphyrins and Porphyrias becoming held May 16 – 18, 2013 in Lucerne, Switzerland. Particularly, Alnylam scientists and collaborators at the Icahn College of Medicine at Mount Sinai in New York City provided data from pre-clinical types of the individual disease displaying that RNAi therapeutics targeting ALAS-1 can completely block the abnormal production of toxic intermediates of the heme biosynthesis pathway that cause the symptoms and disease pathology of AIP.

Watch out for that, as they’re easy to spot.. Alternative media blows the lid on Big Pharma’s substantial bribery network Two of the very most influential substitute media organizations on the ‘net – – and – – have blown the lid widely open on Big Pharma’s massive bribery network. Through exceptional interviews with pharma insiders, InfoWars and NaturalNews did what the mainstream mass media refuses to do: grant a system to credible whistleblowers who are exposing the systematic, criminal Big Pharma bribing of doctors who willingly acknowledge kickbacks to write prescriptions for high-income pharmaceuticals. These revelations are surfacing on the heels of the drug industry’s largest settlement ever sold: GlaxoSmithKline’s $3 billion fine and guilty plea to committing felony crimes could connect with one of the key whistleblowers who initiated that nine-yr DOJ investigation, and he continued the record with shocking allegations about off-label pharmaceutical advertising and the systematic bribery of doctors This tale isn’t over.